Vaxart Files 8-K: Other Events & Exhibits
Ticker: VXRT · Form: 8-K · Filed: Jan 21, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, corporate-update
TL;DR
Vaxart dropped an 8-K on Jan 21 for Jan 13 events - check it for updates.
AI Summary
Vaxart, Inc. filed an 8-K on January 21, 2025, reporting an event that occurred on January 13, 2025. The filing pertains to "Other Events" and "Financial Statements and Exhibits." Vaxart, Inc. is a biotechnology company focused on developing oral vaccines.
Why It Matters
This 8-K filing indicates Vaxart is disclosing material information or events, which could impact investor understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant updates, but the specific nature of the 'Other Events' and 'Exhibits' requires further investigation to assess the precise risk.
Key Numbers
- 001-35285 — Commission File Number (Identifies Vaxart's SEC filing history)
- 59-1212264 — IRS Employer Identification No. (Tax identification for Vaxart)
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- January 13, 2025 (date) — Earliest event reported
- January 21, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- South San Francisco (location) — Business address city
FAQ
What specific 'Other Events' are being reported by Vaxart, Inc. on January 13, 2025?
The filing indicates 'Other Events' as an item reported, but the specific details of these events are not provided in the provided text excerpt.
What is the significance of the 'Financial Statements and Exhibits' being filed?
This indicates that Vaxart is providing updated financial information or relevant supporting documents as part of this report.
When was Vaxart, Inc. incorporated?
Vaxart, Inc. was incorporated in Delaware.
What is Vaxart's primary business according to the filing?
Vaxart, Inc. is in the business of Biological Products (excluding diagnostic substances).
What was Vaxart's former company name before 2016?
Before April 13, 2016, Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-01-21 09:41:24
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
Filing Documents
- vxrt20250120_8k.htm (8-K) — 30KB
- ex_767659.htm (EX-99.1) — 13KB
- ex_767668.htm (EX-99.2) — 19KB
- 0001437749-25-001459.txt ( ) — 202KB
- vxrt-20250113.xsd (EX-101.SCH) — 3KB
- vxrt-20250113_def.xml (EX-101.DEF) — 11KB
- vxrt-20250113_lab.xml (EX-101.LAB) — 15KB
- vxrt-20250113_pre.xml (EX-101.PRE) — 11KB
- vxrt20250120_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On January 13, 2025, Vaxart, Inc. (the "Company") issued a press release announcing that an independent Data Safety Monitoring Board recommended that the Company's Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator proceed without any modifications. On January 14, 2025, the Company issued a press release, providing business updates on its COVID-19, norovirus, and influenza programs, as well as other matters. Copies of the press releases are attached herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and, other than the quotes by Steven Lo and Dr. James F. Cummings, are incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release dated January 13, 2025. 99.2 Press Release dated January 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 21, 2025 VAXART, INC. /s/ Phillip Lee Phillip Lee Chief Financial Officer